*The centralised procedure is* **compulsory for:**

	- *human* immunodeficiency *virus (HIV) or acquired immune deficiency syndrome (AIDS);*
	- *canc*e*r;*
	- *diabetes;*
	- neurodegenerative diseases;
	- auto immune and other immune dysfunctions;
	- viral dise*ases.*

It is optional for other medicines:


Today, the great majority of new, innovative medicines pass through the centralised authorisation procedure in order to be marketed in the EU.

If a company wishes to request marketing authorisation in several EU Member States for a medicine that is outside the scope of the centralised procedure, it may use one of the following routes, as also clarified in the EMA website:


In case of Radiopharmaceuticals, that are used extensively to treat people with cancer, centralised procedure will be the proceeding to be followed.
